Pulmonary edema resident survival guide: Difference between revisions
Line 546: | Line 546: | ||
====Medications==== | ====Medications==== | ||
{| class="wikitable" | {| class="wikitable" | ||
! Drug Class | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Drug Class | ||
! Drug | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Drug | ||
! Daily dose | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Daily dose | ||
! Maximum daily dose | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Maximum daily dose | ||
|- | |- | ||
| rowspan="3" | [[Loop diuretics|'''Loop diuretics''']]||[[Furosemide]] <br> ''(duration of action: 6 to 8 h)'' ||PO dose for chronic heart failure: 20 to 40 mg once or twice<br> | | rowspan="3" style="background:#DCDCDC;" align="center" + | [[Loop diuretics|'''Loop diuretics''']]||[[Furosemide]] <br> ''(duration of action: 6 to 8 h)'' ||PO dose for chronic heart failure: 20 to 40 mg once or twice<br> | ||
IV dose for acute heart failure: | IV dose for acute heart failure: | ||
: Initial dose given slowly (1 to 2 minutes)<br> | : Initial dose given slowly (1 to 2 minutes)<br> | ||
Line 564: | Line 564: | ||
| [[Torsemide]] <br> ''(duration of action: 12 to 16 h)''|| PO dose for chronic heart failure: 10 to 20 mg once|| 200 mg | | [[Torsemide]] <br> ''(duration of action: 12 to 16 h)''|| PO dose for chronic heart failure: 10 to 20 mg once|| 200 mg | ||
|- | |- | ||
| rowspan="3" | [[Thiazide diuretics|'''Thiazide diuretics''']] || [[Chlorothiazide]] <br> ''(duration of action: 6 to 12 h)''|| PO: 250 to 500 mg once or twice|| 1000 mg | | rowspan="3" style="background:#DCDCDC;" align="center" + | [[Thiazide diuretics|'''Thiazide diuretics''']] || [[Chlorothiazide]] <br> ''(duration of action: 6 to 12 h)''|| PO: 250 to 500 mg once or twice|| 1000 mg | ||
|- | |- | ||
| [[Hydrochlorothiazide]] <br> ''(duration of action: 6 to 12 h)''|| PO: 25 mg once or twice|| 200 mg | | [[Hydrochlorothiazide]] <br> ''(duration of action: 6 to 12 h)''|| PO: 25 mg once or twice|| 200 mg | ||
Line 570: | Line 570: | ||
| [[Metolazone]] <br> ''(duration of action: 12 to 24 h)''|| PO: 2.5 mg once|| 20 mg | | [[Metolazone]] <br> ''(duration of action: 12 to 24 h)''|| PO: 2.5 mg once|| 20 mg | ||
|- | |- | ||
| rowspan="3" | '''K<sup>+</sup>- sparing diuretic'''|| [[Amiloride]] <br> ''(duration of action: 24 h)''|| PO: 5 mg once|| 20 mg | | rowspan="3" style="background:#DCDCDC;" align="center" + | '''K<sup>+</sup>- sparing diuretic'''|| [[Amiloride]] <br> ''(duration of action: 24 h)''|| PO: 5 mg once|| 20 mg | ||
|- | |- | ||
| [[Spironolactone]] <br> ''(duration of action: 1 to 3 h)''|| PO: 12.5 to 25.0 mg once|| 50 mg | | [[Spironolactone]] <br> ''(duration of action: 1 to 3 h)''|| PO: 12.5 to 25.0 mg once|| 50 mg | ||
Line 576: | Line 576: | ||
| [[Triamterene]] <br> ''(duration of action: 7 to 9 h)''|| PO: 50 to 75 mg twice|| 200 mg | | [[Triamterene]] <br> ''(duration of action: 7 to 9 h)''|| PO: 50 to 75 mg twice|| 200 mg | ||
|- | |- | ||
| rowspan="3" | [[ACE inhibitors|'''ACE inhibitors''']] || [[Enalapril]] || 2.5 mg twice|| 10 to 20 mg twice | | rowspan="3" style="background:#DCDCDC;" align="center" + | [[ACE inhibitors|'''ACE inhibitors''']] || [[Enalapril]] || 2.5 mg twice|| 10 to 20 mg twice | ||
|- | |- | ||
| [[Lisinopril]] || 2.5 to 5 mg once|| 20 to 40 mg once | | [[Lisinopril]] || 2.5 to 5 mg once|| 20 to 40 mg once | ||
Line 582: | Line 582: | ||
| [[Ramipril]] ||1.25 to 2.5 mg once|| 10 mg once | | [[Ramipril]] ||1.25 to 2.5 mg once|| 10 mg once | ||
|- | |- | ||
| rowspan="3" | [[ARBs|'''ARBs''']] || [[Candesartan]] || 4 to 8 mg once|| 32 mg once | | rowspan="3" style="background:#DCDCDC;" align="center" + | [[ARBs|'''ARBs''']] || [[Candesartan]] || 4 to 8 mg once|| 32 mg once | ||
|- | |- | ||
| [[Losartan]] || 25 to 50 mg once || 50 to 150 mg once | | [[Losartan]] || 25 to 50 mg once || 50 to 150 mg once | ||
Line 588: | Line 588: | ||
| [[Valsartan]] || 20 to 40 mg twice|| 160 mg twice | | [[Valsartan]] || 20 to 40 mg twice|| 160 mg twice | ||
|- | |- | ||
| rowspan="4" | [[Beta blockers|'''Beta blockers''']] || [[Bisoprolol]] || 1.25 mg once|| 10 mg once | | rowspan="4" style="background:#DCDCDC;" align="center" + | [[Beta blockers|'''Beta blockers''']] || [[Bisoprolol]] || 1.25 mg once|| 10 mg once | ||
|- | |- | ||
| [[Carvedilol]] || 3.125 mg twice|| 50 mg twice | | [[Carvedilol]] || 3.125 mg twice|| 50 mg twice | ||
Line 596: | Line 596: | ||
| [[Metoprolol Succinate ER|Metoprolol succinate extended release]] || 12.5 to 25.0 mg once|| 200 mg once | | [[Metoprolol Succinate ER|Metoprolol succinate extended release]] || 12.5 to 25.0 mg once|| 200 mg once | ||
|- | |- | ||
| rowspan="2" | [[Aldosterone antagonists|'''Aldosterone antagonists''']]|| [[Spironolactone]] || 12.5 to 25.0 mg once|| 25 mg once or twice | | rowspan="2" style="background:#DCDCDC;" align="center" + | [[Aldosterone antagonists|'''Aldosterone antagonists''']]|| [[Spironolactone]] || 12.5 to 25.0 mg once|| 25 mg once or twice | ||
|- | |- | ||
| [[Eplerenone]] || 25 mg once|| 50 mg once | | [[Eplerenone]] || 25 mg once|| 50 mg once | ||
|- | |- | ||
| rowspan="3" | '''Inotropes''' || [[Dopamine]] || 5 to 10 mcg/kg/min, OR <br> 10 to 15 mcg/kg/min|| | | rowspan="3" style="background:#DCDCDC;" align="center" + | '''Inotropes''' || [[Dopamine]] || 5 to 10 mcg/kg/min, OR <br> 10 to 15 mcg/kg/min|| | ||
|- | |- | ||
| [[Dobutamine]] || 2.5 to 5 mcg/kg/min, OR <br> 5 to 20 mcg/kg/min|| | | [[Dobutamine]] || 2.5 to 5 mcg/kg/min, OR <br> 5 to 20 mcg/kg/min|| | ||
Line 606: | Line 606: | ||
| [[Milrinone]] || 0.125 to 0.75 mcg/kg/min|| | | [[Milrinone]] || 0.125 to 0.75 mcg/kg/min|| | ||
|- | |- | ||
| rowspan="4" | [[Vasodilators|'''Vasodilators''']] || [[Nitroglycerin]] || 5 to 10 mcg/min, increase dose by 5-10mcg/min <br>every 3-5 mins as tolerated||Max is 400mcg/min | | rowspan="4" style="background:#DCDCDC;" align="center" + | [[Vasodilators|'''Vasodilators''']] || [[Nitroglycerin]] || 5 to 10 mcg/min, increase dose by 5-10mcg/min <br>every 3-5 mins as tolerated||Max is 400mcg/min | ||
|- | |- | ||
| [[Nitroprusside]] || 5 to 10 mcg/min, increase dose by 5-10mcg/min <br>every 5 mins as tolerated||Max is 400mcg/min | | [[Nitroprusside]] || 5 to 10 mcg/min, increase dose by 5-10mcg/min <br>every 5 mins as tolerated||Max is 400mcg/min | ||
Line 616: | Line 616: | ||
|Max is 5mg | |Max is 5mg | ||
|- | |- | ||
| rowspan="2" | '''[[Hydralazine]] and [[isosorbide dinitrate]]''' ||Fixed-dose combination || 37.5 mg [[hydralazine]]/20 mg [[isosorbide dinitrate]] 3 times daily || 75 mg hydralazine/40 mg isosorbide dinitrate 3 times daily | | rowspan="2" style="background:#DCDCDC;" align="center" + | '''[[Hydralazine]] and [[isosorbide dinitrate]]''' ||Fixed-dose combination || 37.5 mg [[hydralazine]]/20 mg [[isosorbide dinitrate]] 3 times daily || 75 mg hydralazine/40 mg isosorbide dinitrate 3 times daily | ||
|- | |- | ||
|Individual doses||[[Hydralazine]]: 25 to 50 mg 3 or 4 times daily<br>[[Isosorbide dinitrate]]: 20 to 30 mg 3 or 4 times daily|| [[Hydralazine]]: 300 mg daily in divided doses <br> [[Isosorbide dinitrate]]: 120 mg daily in divided doses | |Individual doses||[[Hydralazine]]: 25 to 50 mg 3 or 4 times daily<br>[[Isosorbide dinitrate]]: 20 to 30 mg 3 or 4 times daily|| [[Hydralazine]]: 300 mg daily in divided doses <br> [[Isosorbide dinitrate]]: 120 mg daily in divided doses | ||
|- | |- | ||
| [[Digoxin|'''Digoxin''']] || || | | style="background:#DCDCDC;" align="center" + | [[Digoxin|'''Digoxin''']] || || | ||
''Loading dose:'' PO- 10 to 15 mcg/kg (half the total loading dose initially, then 1/4<sup>th</sup> the loading dose every 6 to 8 hours two times), OR<br> | ''Loading dose:'' PO- 10 to 15 mcg/kg (half the total loading dose initially, then 1/4<sup>th</sup> the loading dose every 6 to 8 hours two times), OR<br> | ||
IV- 8 to 12 mcg/kg (half the total loading dose initially, then 1/4<sup>th</sup> the loading dose every 6 to 8 hours two times)<br> | IV- 8 to 12 mcg/kg (half the total loading dose initially, then 1/4<sup>th</sup> the loading dose every 6 to 8 hours two times)<br> | ||
Line 628: | Line 628: | ||
| | | | ||
|- | |- | ||
| rowspan="2" |'''Type III phosphodiesterease inhibitors (PDEIs)''' | | rowspan="2" style="background:#DCDCDC;" align="center" + |'''Type III phosphodiesterease inhibitors (PDEIs)''' | ||
|[[Milrinone]] | |[[Milrinone]] | ||
|Loading dose: IV infusion 50mcg/kg admnistered over 10 min | |Loading dose: IV infusion 50mcg/kg admnistered over 10 min | ||
Line 642: | Line 642: | ||
| | | | ||
|- | |- | ||
| rowspan="2" |'''[[Vasopressin]] Antagonists''' | | rowspan="2" style="background:#DCDCDC;" align="center" + |'''[[Vasopressin]] Antagonists''' | ||
|[[Conivaptan]] | |[[Conivaptan]] | ||
| For euvolemic or hypervolemic hyponatremia, following regimen is used: | | For euvolemic or hypervolemic hyponatremia, following regimen is used: | ||
Line 653: | Line 653: | ||
| | | | ||
|- | |- | ||
|'''For [[Acute respiratory distress syndrome]]''' | | style="background:#DCDCDC;" align="center" + |'''For [[Acute respiratory distress syndrome]]''' | ||
|[[Corticosteroids]] | |[[Corticosteroids]] | ||
Line 664: | Line 664: | ||
| | | | ||
|- | |- | ||
|'''For [[Altitude sickness|high-altitude]] pulmonary edema''' | | style="background:#DCDCDC;" align="center" + |'''For [[Altitude sickness|high-altitude]] pulmonary edema''' | ||
|[[Acetazolamide]] | |[[Acetazolamide]] | ||
Latest revision as of 16:44, 20 March 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2], Farnaz Khalighinejad, MD [3]
Overview
Pulmonary edema is fluid accumulation in the lungs. This fluid accumulation leads to impaired gas exchange and hypoxia. The history of a patient with pulmonary edema varies according to the underlying cause. The most common symptom of pulmonary edema is shortness of breath (dyspnea). Depending on the cause, it may occur acutely or have a gradual onset. When pulmonary edema is due to an acute myocardial infarction chest pain is common symptom. Patients with pulmonary edema usually appear agitated. Physical examination of patients with pulmonary edema is usually remarkable for dyspnea, tachypnea. The presence of abnormal cardiac examination on physical examination is diagnostic of cardiogenic pulmonary edema. Patients with noncardiogenic pulmonary edema may have warm extremities, whereas patients with cardiogenic pulmonary edema may have cool extremities. Pulmonary artery catheterization is the gold standard test for the diagnosis of pulmonary edema. Elevated pulmonary-artery pressure indicates cardiogenic pulmonary edema or pulmonary edema due to volume overload. The main goal of a treatment are alleviate symptoms and improving hemodynamics. The initial management of patients is following the ABCs of resuscitation, that is, airway, breathing, and circulation. Medical treatment of cardiogenic pulmonary edema focuses on preload reduction, afterload reduction and inotropic support.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
- Acute decompensated heart failure
- Acute respiratory distress syndrome
- High altitude pulmonary edema
- Pulmonary embolism
Common Causes
- Congestive heart failure
- Coronary Heart Disease
- Aortic Regurgitation
- Aortic Stenosis
- Mitral Regurgitation
- Mitral Stenosis
- Myocarditis
- Pericardial Disease
- Infection
- Sepsis
Classification
Pulmonary edema may be classified according to etiology into 2 groups:
Cardiogenic pulmonary edema, which can be secondary to:
- Left ventricular failure
- Dysrhythmia
- Left ventricular hypertrophy cardiomyopathy
- Volume overload
- Myocardial Infarction
- Left ventricular outflow obstruction
Non-cardiogenic pulmonary edema which can be secondary to:
- Acute respiratory distress syndrome (ARDS)
- High altitude pulmonary edema
- Neurogenic pulmonary edema
- Reperfusion pulmonary edema
- Re-expansion pulmonary edema
- Others(opioid overdose, salicylate toxicity, viral infections)
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients of pulmonary edema in need of immediate intervention.[1]
Boxes in red signify that an urgent management is needed.
Abbreviations:
BU: Blood urea nitrogen;
COPD: Chronic obstructive pulmonary disease;
D5W: 5% dextrose solution in water ;
HF: Heart failure;
IV: Intravenous;
MAP: Mean arterial pressure;
Na: Sodium;
NSAID: Non steroidal anti-inflammatory drug;
SBP: Systolic blood pressure;
S3: Third heart sound;
Identify cardinal findings that increase the pretest probability of pulmonary edema ❑ Anxiety, restlessness | |||||||||||||||||
Does the patient have any of the following findings that require hospitalization and urgent management?
❑ Dyspnea at rest manifested by tachypnea or oxygen saturation <90% | |||||||||||||||||
Yes | No | ||||||||||||||||
Admit to to a level of care that allows for constant ECG monitoring given the risk of arrhythmia and order a stat chest X-ray | |||||||||||||||||
Initial stabilization: Assess congestion and perfusion: Identify precipitating factor and treat accordingly:
❑ COPD Treat congestion and optimize volume status:
❑ Low sodium diet (<2 g daily)
❑ Consider low dose dopamine infusion for improved diuresis and renal blood flow (IIb-B) Venodilators
Treat low perfusion:
Invasive hemodynamic monitoring: Pulmonary embolism: Aspirin toxicity: Opioid overdose treatment Infections treatment
❑ DO NOT INITIATE ACE INHIBITORS during an acute decompensation Monitor laboratory tests: Management of hyponatremia:
❑ Optimization of chronic home medications | |||||||||||||||||
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.
Abbreviations:
ANA: Antinuclear antibody;
ARDS: Acute respiratory distress syndrome;
BNP: B-type natriuretic peptide;
BUN: Blood urea nitrogen;
CAD: Coronary artery disease;
CBC: Complete blood count;
CCB: Calcium channel blocker;
CHF: Congestive heart failure;
CT: Computed tomography;
CXR: Chest X-ray;
DM: Diabetes mellitus;
ECG: Electrocardiogram;
JVP: Jugular venous pressure;
HF: Heart failure;
HTN: Hypertension;
LVEF: Left ventricular ejection fraction;
LVH: Left ventricular hypertrophy;
MI: Myocardial infarction;
MRI: Magnetic resonance imaging;
NT-pro BNP: N-terminal pro-brain natriuretic peptide;
OCPs: Oral contraceptive pills;
PAWP: Pulmonary artery wedge pressure;
SBP: Systolic blood pressure;
S1: First heart sound;
S3: Third heart sound;
TSH: Thyroid stimulating hormone
Characterize the symptoms: Symptoms of Cardiogenic pulmonary edema
❑ Paroxysmal nocturnal dyspnea Symptoms of Noncardiogenic pulmonary edema Symptoms suggestive of precipitating events
Obtain a detailed history:
❑ Medication history
❑ Family history
❑ Surgical history ❑Recent history
| |||||||||||||||||||||||||||||||||
Examine the patient: General appearance: Vitals: ❑ Pulse
❑ Pulse oximetry (maintain oxygen sat ≥ 94% unless COPD) Weight: Skin Neck examination: Respiratory examination Cardiovascular examination
Abdominal examination Extremity examination Neurological examination Determine status of congestion and perfusion based on physical exam:
Low perfusion at rest (warm vs. cold)
The patient is: | |||||||||||||||||||||||||||||||||
Order tests: Routine (Class I, level of evidence C)
❑ BNP or NT-pro BNP
❑ Chest X-ray of Cardiogenic pulmonary edema (Class I, level of evidence C)
❑ Chest X-ray findings of non-cardiogenic edema ❑ ECG (to help identify the cause of heart failure)
❑ 2-D echocardiography with Doppler
❑ Radionuclide ventriculography or MRI
❑ Coronary angiography looking for CAD Order additional tests to rule out other etiologies: | |||||||||||||||||||||||||||||||||
Consider alternative diagnoses:
| |||||||||||||||||||||||||||||||||
Assess the stage of heart failure using the ACCF/AHA staging system to guide chronic therapy
| |||||||||||||||||||||||||||||||||
Prevention of pulmonary edema
Prevention of pulmonary edema | |||||||||||||||||||||||||||
Non-cardiogenic pulmonary edema | Cardiogenic pulmonary edema | ||||||||||||||||||||||||||
❑ Encourage healthy lifestyle and exercise
| ❑ Treat hypertension | ||||||||||||||||||||||||||
Consider additional measures in selected patients:
❑ Administer ACE-I if history of MI or ACS and reduced EF to prevent symptoms and reduce mortality (I-A), in all decreased EF to prevent symptoms (I-A) | |||||||||||||||||||||||||||
Treatment of pulmonary edema
Pulmonary edema treatment based on classification | |||||||||||||||||||||||||
Cardiogenic pulmonary edema | Noncardiogenic pulmonary edema | ||||||||||||||||||||||||
❑ First step is to stabilize the patient by following the ABCs of resuscitation, that is, airway, breathing, and circulation ❑ Any associated arrhythmia or myocardial infarction should be treated appropriately ❑Following drugs are used: ❑ ACE-I or ARB ❑Beta blockers
PLUS
❑ Monitor volume status and adjust dose
| ❑Treatment of the underlying cause is very important ❑ If the cause of pulmonary edema is overdose of opioid overdose:
❑ Salicylate toxicity
❑ High altitude pulmonary edema treatment:
❑Anticoagulants are used for the treatment of pulmonary edema due to pulmonary embolism | ||||||||||||||||||||||||
Medications
Drug Class | Drug | Daily dose | Maximum daily dose |
---|---|---|---|
Loop diuretics | Furosemide (duration of action: 6 to 8 h) |
PO dose for chronic heart failure: 20 to 40 mg once or twice IV dose for acute heart failure:
Initial IV bolus administered slowly over 1 to 2 minutes, then continuous IV infusion rate of 10-40 mg/h |
600 mg |
Bumetanide (duration of action: 4 to 6 h) |
PO dose for chronic heart failure: 0.5 to 1.0 mg once or twice | 10 mg | |
Torsemide (duration of action: 12 to 16 h) |
PO dose for chronic heart failure: 10 to 20 mg once | 200 mg | |
Thiazide diuretics | Chlorothiazide (duration of action: 6 to 12 h) |
PO: 250 to 500 mg once or twice | 1000 mg |
Hydrochlorothiazide (duration of action: 6 to 12 h) |
PO: 25 mg once or twice | 200 mg | |
Metolazone (duration of action: 12 to 24 h) |
PO: 2.5 mg once | 20 mg | |
K+- sparing diuretic | Amiloride (duration of action: 24 h) |
PO: 5 mg once | 20 mg |
Spironolactone (duration of action: 1 to 3 h) |
PO: 12.5 to 25.0 mg once | 50 mg | |
Triamterene (duration of action: 7 to 9 h) |
PO: 50 to 75 mg twice | 200 mg | |
ACE inhibitors | Enalapril | 2.5 mg twice | 10 to 20 mg twice |
Lisinopril | 2.5 to 5 mg once | 20 to 40 mg once | |
Ramipril | 1.25 to 2.5 mg once | 10 mg once | |
ARBs | Candesartan | 4 to 8 mg once | 32 mg once |
Losartan | 25 to 50 mg once | 50 to 150 mg once | |
Valsartan | 20 to 40 mg twice | 160 mg twice | |
Beta blockers | Bisoprolol | 1.25 mg once | 10 mg once |
Carvedilol | 3.125 mg twice | 50 mg twice | |
Carvedilol CR | 10 mg once | 80 mg once | |
Metoprolol succinate extended release | 12.5 to 25.0 mg once | 200 mg once | |
Aldosterone antagonists | Spironolactone | 12.5 to 25.0 mg once | 25 mg once or twice |
Eplerenone | 25 mg once | 50 mg once | |
Inotropes | Dopamine | 5 to 10 mcg/kg/min, OR 10 to 15 mcg/kg/min |
|
Dobutamine | 2.5 to 5 mcg/kg/min, OR 5 to 20 mcg/kg/min |
||
Milrinone | 0.125 to 0.75 mcg/kg/min | ||
Vasodilators | Nitroglycerin | 5 to 10 mcg/min, increase dose by 5-10mcg/min every 3-5 mins as tolerated |
Max is 400mcg/min |
Nitroprusside | 5 to 10 mcg/min, increase dose by 5-10mcg/min every 5 mins as tolerated |
Max is 400mcg/min | |
Nesiritide | 2 mcg/kg bolus; then 0.01 mcg/kg/minute continuous infusion | Max of 0.03 mcg/kg/minute | |
Morphine sulfate | 2.5 – 5 mg bolus | Max is 5mg | |
Hydralazine and isosorbide dinitrate | Fixed-dose combination | 37.5 mg hydralazine/20 mg isosorbide dinitrate 3 times daily | 75 mg hydralazine/40 mg isosorbide dinitrate 3 times daily |
Individual doses | Hydralazine: 25 to 50 mg 3 or 4 times daily Isosorbide dinitrate: 20 to 30 mg 3 or 4 times daily |
Hydralazine: 300 mg daily in divided doses Isosorbide dinitrate: 120 mg daily in divided doses | |
Digoxin |
Loading dose: PO- 10 to 15 mcg/kg (half the total loading dose initially, then 1/4th the loading dose every 6 to 8 hours two times), OR
|
||
Type III phosphodiesterease inhibitors (PDEIs) | Milrinone | Loading dose: IV infusion 50mcg/kg admnistered over 10 min
Maintenance dose: IV infusion: 0.375 to 0.75 mcg/kg/minute Inhibit degradation of cyclic AMP |
|
Enoximone | IV dose ranging from two doses of 25 mg to two doses of 100 mg. | ||
Vasopressin Antagonists | Conivaptan | For euvolemic or hypervolemic hyponatremia, following regimen is used:
Loading dose: IV: 20 mg infused over 30 minutes followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2 to 4 days |
Maximum dose of 40 mg over 24 hours |
Tolvaptan | |||
For Acute respiratory distress syndrome | Corticosteroids | Moderate-dose IV methylprednisolone, to 120 mg per kg per day for up to 25 days
40 mg of enoxaparin [Lovenox] or 5,000 units of dalteparin [Fragmin] subcutaneously per day) or low-dose, unfractionated heparin(5,000 units subcutaneously twice daily) |
|
For high-altitude pulmonary edema | Acetazolamide | 250 mg PO q12h
4 mg PO q6h |
References
- ↑ Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH; et al. (2013). "2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 128 (16): 1810–52. doi:10.1161/CIR.0b013e31829e8807. PMID 23741057.
- ↑ Perna, ER.; Macín, SM.; Parras, JI.; Pantich, R.; Farías, EF.; Badaracco, JR.; Jantus, E.; Medina, F.; Brizuela, M. (2002). "Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema". Am Heart J. 143 (5): 814–20. PMID 12040342. Unknown parameter
|month=
ignored (help) - ↑ McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K; et al. (2012). "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC". Eur Heart J. 33 (14): 1787–847. doi:10.1093/eurheartj/ehs104. PMID 22611136.
- ↑ Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A; et al. (2006). "The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure". Br J Gen Pract. 56 (526): 327–33. PMC 1837840. PMID 16638247.